Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Report
April 2, 2025
Ulcerative Colitis – Unmet Need – Unmet Need – Moderate to Severe Ulcerative Colitis (US/EU)
TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine ’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s Entyvio), a JAK inhibitor (Pfizer’s Xeljanz), and an IL-12/23 inhibitor…
Report
July 23, 2024
Ulcerative Colitis – Current Treatment – Current Treatment: Physician Insights – Ulcerative Colitis (EU5)
Many well-established therapies are available to treat ulcerative colitis (UC) in the EU5. TNF-alpha inhibitors (Janssen’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s Entyvio), and…
Report
June 19, 2024
Crohn’s Disease – Current Treatment – Current Treatment: Physician Insights – Crohn’s Disease (EU5)
Multiple well-established therapies are available to treat Crohn’s disease (CD). The mostly widely used biologics, the TNF-α inhibitors (e.g., Janssen / Merck’s Remicade, AbbVie / Eisai’s…
